ES2573539T3 - Inhibidor de la cristalización y su uso en cápsulas de gelatina - Google Patents

Inhibidor de la cristalización y su uso en cápsulas de gelatina Download PDF

Info

Publication number
ES2573539T3
ES2573539T3 ES06738862.9T ES06738862T ES2573539T3 ES 2573539 T3 ES2573539 T3 ES 2573539T3 ES 06738862 T ES06738862 T ES 06738862T ES 2573539 T3 ES2573539 T3 ES 2573539T3
Authority
ES
Spain
Prior art keywords
glyceryl
crystallization inhibitor
capsule
gelatin capsules
excipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06738862.9T
Other languages
English (en)
Inventor
Tomas Andrysek
Ales Vrana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Czech Industries sro
Original Assignee
Teva Czech Industries sro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36675980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2573539(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Czech Industries sro filed Critical Teva Czech Industries sro
Application granted granted Critical
Publication of ES2573539T3 publication Critical patent/ES2573539T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una cápsula de gelatina blanda, que comprende: a. una cubierta de gelatina; y, b. un contenido de cápsula, que comprende: un principio activo insoluble en agua disuelto en un excipiente, comprendiendo el excipiente: un inhibidor de la cristalización presente en una cantidad de un 2-10 % p/p con respecto al peso del contenido de la cápsula, seleccionándose el inhibidor de la cristalización entre: un compuesto monoacilglicerol que se selecciona entre el grupo que consiste en monooleato de glicerilo, monolinoleato de glicerilo, monopalmitato de glicerilo, monoestearato de glicerilo, monolaurato de glicerilo, monocaprilato de glicerilo, monocaprato de glicerilo y combinaciones de los mismos, y un disolvente hidrófilo que comprende etanol.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
    imagen2
ES06738862.9T 2005-03-21 2006-03-16 Inhibidor de la cristalización y su uso en cápsulas de gelatina Expired - Lifetime ES2573539T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66482605P 2005-03-21 2005-03-21
US664826P 2005-03-21
PCT/US2006/009859 WO2006102157A1 (en) 2005-03-21 2006-03-16 Crystallization inhibitor and its use in gelatin capsules

Publications (1)

Publication Number Publication Date
ES2573539T3 true ES2573539T3 (es) 2016-06-08

Family

ID=36675980

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06738862.9T Expired - Lifetime ES2573539T3 (es) 2005-03-21 2006-03-16 Inhibidor de la cristalización y su uso en cápsulas de gelatina

Country Status (10)

Country Link
US (1) US8673351B2 (es)
EP (1) EP1885342B8 (es)
CN (1) CN101141953A (es)
CO (1) CO6321129A2 (es)
ES (1) ES2573539T3 (es)
HU (1) HUE029192T2 (es)
IL (1) IL185729A0 (es)
MX (1) MX2007011250A (es)
PL (1) PL1885342T3 (es)
WO (1) WO2006102157A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007271088A1 (en) * 2006-07-06 2008-01-10 Ares Trading S.A. An oral pharmaceutical composition of an anilinopyrimidine, its preparation and use thereof
US9011908B2 (en) 2009-04-06 2015-04-21 Banner Life Sciences Llc Progesterone solutions for increased bioavailability
CN101721931B (zh) * 2009-11-26 2012-08-08 广州普正生物科技有限公司 一种多相混悬系统及其制备方法与应用
US8900631B2 (en) 2011-04-28 2014-12-02 Health Science Funding, LLC Dosage form to increase prasterone bioavailability
WO2013144976A2 (en) * 2012-03-28 2013-10-03 Medreich Limited Chewable soft gelatin capsule dosage form of mucolytic agents
WO2015022349A1 (en) * 2013-08-14 2015-02-19 Ratiopharm Gmbh Dosage form comprising enzalutamide
EA036036B1 (ru) * 2014-11-07 2020-09-16 Сигмойд Фарма Лимитед Композиции, содержащие циклоспорин
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN113544117A (zh) * 2019-02-06 2021-10-22 埃默拉尔德健康制药公司 大麻二酚衍生物的调配物和其作为2型大麻素受体（cb２）的调节剂的用途
JP2022529781A (ja) 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド サイロシビンによるうつ病及び他の様々な障害の治療

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE445174B (sv) * 1978-03-07 1986-06-09 Sandoz Ag Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
DE3629386A1 (de) * 1986-08-29 1988-03-03 Scherer Gmbh R P Gelatinekapseln und verfahren zu ihrer herstellung
DE68900991D1 (de) 1988-01-29 1992-04-23 Sankyo Co Cyclosporin-zusammensetzungen.
FR2683225B1 (fr) 1991-10-31 1993-12-31 Gattefosse Sa Procede pour ameliorer une huile glycerolysee.
DE4221491C2 (de) 1992-06-29 1994-09-29 Pohl Boskamp Gmbh Chem Pharma Verfahren zur Herstellung von Weichgelatinekapseln
ES2308955T5 (es) 1993-09-28 2012-04-03 R.P. Scherer Gmbh Fabricación de cápsulas de gelatina blanda
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
JPH10211425A (ja) * 1997-01-29 1998-08-11 Fuji Capsule Kk カプセルの乾燥方法
NZ510991A (en) * 1997-03-05 2002-11-26 Sugen Inc Use of formulations for hydrophobic pharmaceutical agents in treatment or prevention of cell proliferative disorders
US6063762A (en) * 1997-12-05 2000-05-16 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition
ID25908A (id) 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
EP1067908B9 (en) * 1998-04-01 2007-01-24 Jagotec Ag Taxane microemulsions
JP3500313B2 (ja) * 1998-10-27 2004-02-23 花王株式会社 カプセル粒子の水分除去方法
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6652880B1 (en) 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
US20020049157A1 (en) 1999-08-25 2002-04-25 Jiangping Wu Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
WO2002024172A1 (en) * 2000-09-22 2002-03-28 Galephar M/F Pharmaceutical semi-solid composition of isotretinoin
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US20040033257A1 (en) * 2002-05-30 2004-02-19 Strides Inc. Pharmaceutical formulation in a drug delivery system and process for preparing the same
GB2391473B (en) * 2002-08-02 2004-07-07 Satishchandra Punambhai Patel Pharmaceutical compositions
GB2391472B (en) * 2002-08-02 2004-12-08 Satishchandra Punambhai Patel Pharmaceutical compositions
US7025911B2 (en) * 2002-09-13 2006-04-11 Freund Corporation Manufacturing method for oral quick-dissolving seamless capsule
JP2004262774A (ja) * 2003-02-20 2004-09-24 Freunt Ind Co Ltd シームレスカプセル
IL159729A0 (en) 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
US20050220825A1 (en) * 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone

Also Published As

Publication number Publication date
US20110020438A1 (en) 2011-01-27
CN101141953A (zh) 2008-03-12
CO6321129A2 (es) 2011-09-20
WO2006102157A1 (en) 2006-09-28
MX2007011250A (es) 2007-11-14
IL185729A0 (en) 2008-01-06
US8673351B2 (en) 2014-03-18
PL1885342T3 (pl) 2016-10-31
EP1885342B1 (en) 2016-03-09
EP1885342A1 (en) 2008-02-13
HUE029192T2 (en) 2017-02-28
EP1885342B8 (en) 2016-06-22

Similar Documents

Publication Publication Date Title
ES2532948T3 (es) Composición tópica para el tratamiento de queratosis actínica
ES2508290T3 (es) Composición farmacéutica para la administracón de compuestos de inhibición del receptor de tirosina cinasa (RTKI) al ojo
ES2575565T3 (es) Procedimiento para la preparación de monohidrato de treprostinilo y su utilización para el almacenamiento y el envío
ES2545395T3 (es) Asociación de ivermectina con brimonidina para el tratamiento o prevención de la rosácea
RU2445312C2 (ru) ПРОИЗВОДНЫЕ 2-МЕТИЛМОРФОЛИН ПИРИДО-, ПИРАЗО- И ПИРИМИДО-ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR
ES2539861T3 (es) Formulaciones en emulsión de clevidipina que contienen agentes antimicrobianos
ES2546847T3 (es) Formulaciones de un inhibidor de la Src/Abl
CO6290641A2 (es) Preparacion de capsula que contiene los ingredientes farmaceuticamente activos liquidos y solidos, la cual presenta exelentes propiedades de los ingredientes farmaceuticamente activos
UY29200A1 (es) Sistema de cápsula blanda sin gelatina
UY31406A1 (es) "producto de dispersion solida que contiene un compuesto a base de n-aril urea".
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
JP2015506989A5 (es)
RU2015115127A (ru) Жидкие лекарственные композиции апиксабана
MX2009009997A (es) Preparacion de la capsula de tamibarotene.
BRPI0710483B1 (pt) Dispositivo compreendendo composições com fenilefrina, cloridrato de fenilefrina, bromidrato de fenilefrina, e misturas das mesmas e Kits úteis para o tratamento de doenças respiratórias
AR045094A1 (es) Formulaciones liofilizadas de cci-779
ES2720954T3 (es) Formulaciones estabilizadas de estatina
AR076305A1 (es) Composiciones de capsulas biodisponibles de compuesto alfa-(n-sulfonamido) acetamida amorfo
BR112020008077A2 (pt) composição farmacêutica, composição farmacêutica para aplicação tópica e uso de uma composição tópica
AR067491A1 (es) Preparacion recubierta
DOP2012000264A (es) Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan
ES2576740T3 (es) Composiciones farmacéuticas tópicas que incluyen REL-N-[6-[(2R,6S)-2,6-dimetil-4-morfolinil]-3-piridinil]-2-metil-4'-(trifluorometoxi)-[1,1'-bifenil]-3-carboxamida
HRP20221241T1 (hr) Oralna otopina koja sadrži soli lisdeksamfetamina
CO6321129A2 (es) Inhibidor de la cristalizacion y su uso en capsulas de gelatina
AR054238A1 (es) Composicion farmaceutica que contiene una biguanida y un derivado de tiazolidindiona